Table 1.
Effect of ceftriaxone plus sulbactam with VRP1034 on GSH, GSSG levels in cadmium exposed group after 21 days of treatment.
| Groups | Plasma | Brain | Liver | Kidney | ||||
|---|---|---|---|---|---|---|---|---|
| GSH | GSSG | GSH | GSSG | GSH | GSSG | GSH | GSSG | |
| Control group | 3.96±0.96 | 0.81±0.17 | 4.89±0.88 | 0.55±0.11 | 5.78±0.55 | 0.64±0.06 | 2.60±0.04 | 0.54±0.13 |
| Cadmium exposed group | 1.55±0.48*** | 1.03±0.64ns | 2.25±1.01*** | 0.89±0.091*** | 2.69±0.33*** | 0.91±0.05*** | 1.87±0.08*** | 0.71±0.15* |
| Ceftriaxone plus sulbactam with VRP1034 treated group | 2.09±0.85ns | 0.78±0.11ns | 3.96±0.66*** | 0.64±0.10*** | 4.00±0.62*** | 0.77±0.08*** | 2.39±0.17*** | 0.60±0.09ns |
All data are Mean ± SD of each group. The GSH and GSSG levels were expressed in the plasma (mg/dL) whereas in the tissues (µmol/g tissue). Newman-Keuls test was performed for statistical significance between control group vs Cd exposed group and Cd exposed group vs ceftriaxone plus sulbactam with VRP1034 treated group.
***
Where p<0.001 (highly significant)
**
p<0.01(significant)
*
p<0.05 (significant)
Ns
p>0.05 (non significant).